Artelo Biosciences Inc (ARTL) Stock Price, Quote & News

Company Profile

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7049

Website: artelobio.com

Address:

505 Lomas Santa Fe, Suite 160, Solana Beach, United States

PureTrades Apr. 25 at 4:01 PM

$ARTL $6.00 by Friday. ☀️☀️☀️☀️☀️☀️☀️☀️☀️☀️☀️☀️

0 · Reply

RoyalImperial Apr. 24 at 9:32 PM

MITQ looking ready, keep eyes on this one. Latest news + contracts rolling in Low float (~sub 10M) NO dilution Record earnings trend 📈. MITQ super undervalued-The entire company trades at 5.5M. It’s sitting on $3.9M in cash. That means you’re effectively buying the entire operating business $18M+ in annual revenue, proprietary products. $EFOI $EEIOQ $LIMN $ARTL /.121

0 · Reply

PureTrades Apr. 24 at 8:44 PM

$ARTL Check this out everyone. I’m LOADING!!!! 🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋

0 · Reply

PureTrades Apr. 24 at 6:05 PM

$ARTL TIGHTENING RANGE… OPPORTUNITY!!!!!!!

0 · Reply

PureTrades Apr. 24 at 4:06 PM

$HKIT $ARTL Top Two Picks. Buying both… ARTL breakout at $4.29 HKIT breakout $1.25 🌋🌋🌋🌋🌋⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️

0 · Reply

PureTrades Apr. 24 at 2:39 PM

$ARTL After hours $5

1 · Reply

Adubstradesmini Apr. 24 at 2:27 PM

$ARTL 5-6$ very short term 15-16$ mid term

0 · Reply

dogood Apr. 24 at 2:20 PM

$ARTL let’s break $5 today

0 · Reply

FonsieTrader Apr. 24 at 1:49 PM

$ARTL Setting up

0 · Reply

NorthernMonkey1 Apr. 24 at 1:37 PM

Nice low for new buyers $ROLR $ONMD $ARTL 👀

0 · Reply

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Apr 7, 2026, 7:50 AM EDT - 18 days ago

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Mar 30, 2026, 4:46 PM EDT - 25 days ago

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 27, 2026, 10:40 AM EDT - 4 weeks ago

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 27, 2026, 9:36 AM EDT - 4 weeks ago

Artelo Biosciences Stock Soars After Withdrawing SEC Filing

Mar 25, 2026, 4:05 PM EDT - 4 weeks ago

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

Mar 25, 2026, 7:31 AM EDT - 4 weeks ago

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

Mar 18, 2026, 3:14 PM EDT - 5 weeks ago

Nano-Cap Artelo Biosciences Stock Explodes — Glaucoma Study Collaboration Ignites Rally

Mar 18, 2026, 10:41 AM EDT - 5 weeks ago

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

YYGH

Mar 18, 2026, 8:07 AM EDT - 5 weeks ago

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Mar 18, 2026, 7:41 AM EDT - 5 weeks ago

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

Mar 6, 2026, 8:00 AM EST - 7 weeks ago

Artelo Biosciences Announces Reverse Stock Split

Feb 24, 2026, 8:00 AM EST - 2 months ago

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Jan 30, 2026, 11:00 AM EST - 3 months ago

Artelo Biosciences Transcript: AGM 2026

Dec 23, 2025, 9:00 AM EST - 4 months ago

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

Nov 12, 2025, 8:00 AM EST - 5 months ago

Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 8:30 AM EST - 6 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Oct 27, 2025, 8:00 AM EDT - 6 months ago

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

Oct 15, 2025, 9:15 AM EDT - 6 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

Oct 1, 2025, 4:05 PM EDT - 7 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

Sep 30, 2025, 8:30 AM EDT - 7 months ago

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Sep 29, 2025, 7:15 PM EDT - 7 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

Sep 29, 2025, 8:30 AM EDT - 7 months ago

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

Sep 5, 2025, 4:05 PM EDT - 8 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

Sep 4, 2025, 8:37 AM EDT - 8 months ago

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Sep 3, 2025, 11:33 AM EDT - 8 months ago

Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

Sep 3, 2025, 8:45 AM EDT - 8 months ago

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

Aug 25, 2025, 7:55 AM EDT - 8 months ago

Artelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Aug 13, 2025, 8:00 AM EDT - 9 months ago

Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 9:15 AM EDT - 9 months ago

Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

Aug 4, 2025, 7:30 AM EDT - 9 months ago

Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset

Aug 1, 2025, 7:45 AM EDT - 9 months ago

Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression

Jul 9, 2025, 7:50 AM EDT - 10 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium

Jul 8, 2025, 3:06 PM EDT - 10 months ago

Artelo Biosciences Analyst See It As An Emerging Biotech

Jul 7, 2025, 7:45 AM EDT - 10 months ago

Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model

Jun 30, 2025, 7:45 AM EDT - 10 months ago

Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain

Jun 26, 2025, 8:00 AM EDT - 10 months ago

Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing

Jun 5, 2025, 9:00 AM EDT - 11 months ago

Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study

Jun 2, 2025, 9:00 AM EDT - 11 months ago

New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression

May 13, 2025, 8:00 AM EDT - 1 year ago

Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:45 AM EDT - 1 year ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results

Feb 14, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex®

Feb 11, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland

Jan 13, 2025, 9:00 AM EST - 1 year ago

Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12

Dec 9, 2024, 9:15 AM EST - 1 year ago

Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia

Nov 18, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit

Nov 13, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium

Nov 5, 2024, 8:30 AM EST - 1 year ago

Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health's “Preclinical Screening Platform for Pain” Program

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Artelo Biosciences Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 9, 2024, 9:00 AM EDT - 1 year ago

Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Artelo Biosciences Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Apr 23, 2024, 10:50 AM EDT - 2 years ago

Artelo Biosciences Transcript: Fireside Chat

PureTrades Apr. 25 at 4:01 PM

$ARTL $6.00 by Friday. ☀️☀️☀️☀️☀️☀️☀️☀️☀️☀️☀️☀️

0 · Reply

RoyalImperial Apr. 24 at 9:32 PM

0 · Reply

PureTrades Apr. 24 at 8:44 PM

$ARTL Check this out everyone. I’m LOADING!!!! 🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋🌋

0 · Reply

PureTrades Apr. 24 at 6:05 PM

$ARTL TIGHTENING RANGE… OPPORTUNITY!!!!!!!

0 · Reply

PureTrades Apr. 24 at 4:06 PM

$HKIT $ARTL Top Two Picks. Buying both… ARTL breakout at $4.29 HKIT breakout $1.25 🌋🌋🌋🌋🌋⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️

0 · Reply

PureTrades Apr. 24 at 2:39 PM

$ARTL After hours $5

1 · Reply

Adubstradesmini Apr. 24 at 2:27 PM

$ARTL 5-6$ very short term 15-16$ mid term

0 · Reply

dogood Apr. 24 at 2:20 PM

$ARTL let’s break $5 today

0 · Reply

FonsieTrader Apr. 24 at 1:49 PM

$ARTL Setting up

0 · Reply

NorthernMonkey1 Apr. 24 at 1:37 PM

Nice low for new buyers $ROLR $ONMD $ARTL 👀

0 · Reply

NorthernMonkey1 Apr. 24 at 1:34 PM

Letting $ROLR breath $ARTL looks fun for the next 30 mins or so

0 · Reply

Adubstradesmini Apr. 24 at 1:32 PM

$ARTL brewing up

0 · Reply

NorthernMonkey1 Apr. 24 at 1:31 PM

$ARTL 👀

0 · Reply

Ozcorp Apr. 24 at 11:21 AM

$KUST $ARTL so which will run today ??

0 · Reply

Adubstradesmini Apr. 24 at 10:55 AM

$ARTL

0 · Reply

FonsieTrader Apr. 24 at 10:03 AM

$SKLZ I wouldn’t be surprised to see money start flowing into $ARTL 👀 → Low float → High short interest narrative still alive → Volume starting to build pre-market This is how these moves usually begin… Quiet accumulation → then expansion. If it catches momentum, this can move fast. Watching closely.

0 · Reply

FonsieTrader Apr. 24 at 9:47 AM

$ARTL— pre-market update 👇 +1% with volume starting to show Exactly what you want to see after yesterday’s move → Buyers still around → Holding levels → Early interest building No big move yet… But the setup remains intact ⸻ This is how continuation starts Not explosive… yet But controlled ⸻ If volume keeps building into open This can get interesting fast

0 · Reply

PureTrades Apr. 24 at 8:04 AM

$ARTL $6-$7

0 · Reply

PureTrades Apr. 24 at 6:26 AM

$ARTL Looking like a very strong upward move coming soon (next week), with the bottoming bull flag base formation. 🌋🌋🌋🌋🌋🌋⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️

0 · Reply

PureTrades Apr. 24 at 3:09 AM

$ARTL Buying more at $3.80

0 · Reply

PureTrades Apr. 23 at 11:50 PM

$IQST $ARTL Top two BUYS for tomorrow!!!!!!!!!! ARTL will breakout above $4.15 ⏳⏳⏳⏳⏳⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️

0 · Reply

defineme44 Apr. 23 at 10:30 PM

$ARTL 40

0 · Reply

Market Cap	3.74M
Revenue (ttm)	0.00
Net Income (ttm)	-12.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	240,200
Avg Vol	4,208,884
Day's Range	N/A - N/A
Shares Out	938,000.00
Stochastic %K	15%
Beta	0.41
Analysts	Hold
Price Target	$18.00